US FDA mulls lowering a REMS hurdle for generic drug makers
This article was originally published in SRA
The US Food and Drug Administration has signaled its willingness to facilitate efforts by generic drug sponsors to gain access to brand drugs with a risk evaluation and mitigation strategy (REMS)1. However, whether the agency's proposed policy will stop the alleged practice by brand drug companies of using REMS to block competition is questionable.
You may also be interested in...
Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business.
Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.
Laparoscopic power morcellation to remove uterine fibroids should only be performed with the use of a compatible containment system, and only on women younger than 50, the US FDA said in a newly published safety communication and draft guidance document. See what the president of the gynecologic trade group AAGL, Jubilee Brown, said about it here.